Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer.

ABSTRACT: Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer.

PROVIDER: PRJNA475560 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7290080.fastq.gz	Fastqsanger.gz
	SRR7290230_1.fastq.gz	Fastqsanger.gz
	SRR7290230_2.fastq.gz	Fastqsanger.gz
	SRR7290240_1.fastq.gz	Fastqsanger.gz
	SRR7290240_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 87

Similar Datasets

Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer.

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-06-12 | GSE115611 | GEO

ESR1 mutations maintain higher ER pathway activity relative to vehicle and ERa-WT controls following treatment with Raloxifene or fulvestrant.

Project description:The goal of the study was to understand whether mutations in ERa can promote resistance to various ERa antagonists of the SERD and SERM class. We found that ESR1 mutations can maintain higher ER pathway activity relative to control lines following short-term treatment with ERa antagonists raloxifene or fulvestrant.

2018-06-12 | GSE115564 | GEO

Expression in the Mut- ko/ki (Mut p.M700K) and controls

Project description:Gene expression from 2 livers and 2 hearts from mouse Mut-ko/ki (MUT p.M700K) described in Forny et al JBC 2016 and 3 livers, 2 hearts from littermate controls

2019-09-22 | GSE121060 | GEO

BCCM GEN-ERA

Project description:BCCM collections in the genomic era (BCCM GEN-ERA)

| PRJEB58632 | ENA

Expression in the Mut- ko/ki (Mut p.M700K) and controls

Project description:Expression in the Mut- ko/ki (Mut p.M700K) and controls

| PRJNA495482 | ENA

ChIP-seq experiments of Estrogen Receptor Alpha (ERa) in the human breast cancer cell line T47D stably expressing GFP or neoGATA3

Project description:In this study, we investigated the functions of the most common GATA3 mutation (X308_Splice) that we called “neoGATA3”. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ERa-dependent transcriptional response in tumors carrying this mutations. ChIP-Seq analysis indicated that ERa binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine-tuning of ERa-dependent gene expression.

2020-06-29 | E-MTAB-9121 | biostudies-arrayexpress

RNA-Seq of human cell lines Ishikawa, MCF7 and T47D treated with estrogen, progesterone and their antagonists

Project description:In this study the effect of estrogen (E2) and progesterone (P4) and their antagonists Tamoxifen, and Mifepristone (RU486) were assesed in endometrial epithelial cell line Ishikawa and compared to breast cancer cell lines MCF7 and T47D. Concentrations used for E2 and P4 treatments were 10 -8 M and for antagonists 10 -6 M. RNA-Sequencing (Illumina GenomeAnalyzer IIe) was applied to study global gene expression in three different cell lines. Expression values after hormonal or antagonist treatments in two different time points (3h and 12h) were compared to non-treated cells.

2012-01-05 | E-MTAB-822 | biostudies-arrayexpress

Ligand dependent gene regulation by transient ERa clustered enhancers

Project description:Unliganded Estrogen receptor alpha (ERa) has been implicated in ligand-dependent gene regulation. Upon ligand exposure, ERa binds to several EREs relatively proximal to the pre-marked, or persistent, ERa-bound sites and affects transient but robust gene expression. However, the underlying mechanisms are not fully understood. Here we demonstrate that upon ligand stimulation, persistent sites interact extensively, via chromatin looping, with the proximal transiently ERa-bound sites, forming Ligand Dependent ERa Enhancer Cluster in 3D (LDEC). The E2-target genes are regulated by these clustered enhancers but not by the H3K27Ac super-enhancers. Further, CRISPR-based deletion of TFF1 persistent site disrupts the formation of its LDEC resulting in the loss of E2-dependent expression of TFF1 and its neighboring genes within the same TAD. The LDEC overlap with nuclear ERa condensates that coalesce in a ligand and persistent site dependent manner. Furthermore, formation of clustered enhancers, as well as condensates, coincide with the active phase of signaling and their later disappearance results in the loss of gene expression even though persistent sites remain bound by ERa. Our results establish a direct link between ERa condensates, ERa enhancer clusters, and transient, but robust, gene expression in a ligand-dependent fashion.

2019-11-22 | GSE136302 | GEO

Inhibiting Androgen Receptor Splice Variants with Cysteine-Selective Irreversible Covalent Inhibitors to Treat Prostate Cancer

Project description:Prostate cancer (PCa) affects over 250,000 men in the US. Androgen Receptor (AR) signaling inhibitors are the mainstay therapeutics for PCa. Advanced PCa that expresses AR splice variants (AR-SVs) does not respond to current therapeutic strategies. In this manuscript, we uncovered the physicochemical properties of the intrinsically-disordered transactivation domain of AR and AR-SV and developed novel AR irreversible covalent antagonists (SARICA) to the transactivation domain for the treatment of advanced PCa. SARICAs were also used to identify a potential binding region in the AR and AR-SV transactivation domain.

2022-12-31 | GSE215335 | GEO

Methanosarcina mazei strain:Mm Mut 203b | isolate:Mm Mut 203b

Project description:Methanosarcina mazei strain:Mm Mut 203b | isolate:Mm Mut 203b Genome sequencing and assembly

| PRJNA929716 | ENA